Schizophrenia Research
Volume 78, Issue 1 , Pages 87-93 , 1 October 2005

Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression

Received 29 April 2005 ,Revised 7 June 2005 ,Accepted 13 June 2005.

References 

  1. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J. Neurosci. 1996;16:19–30
  2. Belsham B. Glutamate and its role in psychiatric illness. Hum. Psychopharmacol. 2001;16:139–146
  3. Chung HJ, Huang YH, Lau LF, Huganir RL. Regulation of the NMDA receptor complex and trafficking by activity-dependent phosphorylation of the NR2B subunit PDZ ligand. J. Neurosci. 2004;24:10248–10259
  4. Clinton SM, Meador-Woodruff JH. Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder. Neuropsychopharmacology. 2004;29:1353–1362
  5. Clinton SM, Abelson S, Haroutunian V, Davis KL, Meador-Woodruff JH. Neurofilament subunit protein abnormalities in the thalamus in schizophrenia. Thalamus Relat. Syst. 2004;2:265–272
  6. Coyle JT. The GABA–glutamate connection in schizophrenia: which is the proximate cause?. Biochem. Pharmacol. 2004;68:1507–1514
  7. Craddock N, O'Donovan MC, Owen MJ. The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J. Med. Genet. 2005;42:193–204
  8. Fujita A, Kurachi Y. SAP family proteins. Biochem. Biophys. Res. Commun. 2000;269:1–6
  9. Godreau D, Neyroud N, Vranckx R, Hatem S. MAGUKs: not only anchoring proteins. Med. Sci. (Paris). 2004;20:84–88
  10. Iwamoto T, Yamada Y, Hori K, Watanabe Y, Sobue K, Inui M. Differential modulation of NR1–NR2A and NR1–NR2B subtypes of NMDA receptor by PDZ domain-containing proteins. J. Neurochem. 2004;89:100–108
  11. Kim JS. Transmitters for the afferent and efferent systems of the neostriatum and their possible interactions. Adv. Biochem. Psychopharmacol. 1978;19:217–233
  12. Kravariti E, Dixon T, Frith C, Murray R, McGuire P. Association of symptoms and executive function in schizophrenia and bipolar disorder. Schizophr. Res. 2005;74:221–231
  13. Li B, Otsu Y, Murphy TH, Raymond LA. Developmental decrease in NMDA receptor desensitization associated with shift to synapse and interaction with postsynaptic density-95. J. Neurosci. 2003;23:11244–11254
  14. Lynch DR, Guttmann RP. NMDA receptor pharmacology: perspectives from molecular biology. Curr. Drug Targets. 2001;2:215–231
  15. Meador-Woodruff JH, Hogg AJ, Smith RE. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res. Bull. 2001;55:631–640
  16. Meador-Woodruff JH, Clinton SM, Beneyto M, McCullumsmith RE. Molecular abnormalities of the glutamate synapse in the thalamus in schizophrenia. Ann. N.Y. Acad. Sci. 2003;1003:75–93
  17. Murray JB. Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research. J. Psychol. 2002;136:319–327
  18. Naisbitt S, Valtschanoff J, Allison DW, Sala C, Kim E, Craig AM, et al. Interaction of the postsynaptic density-95/guanylate kinase domain-associated protein complex with a light chain of myosin-V and dynein. J. Neurosci. 2000;20:4524–4534
  19. Perez-Otano I, Ehlers MD. Learning from NMDA receptor trafficking: clues to the development and maturation of glutamatergic synapses. Neurosignals. 2004;13:175–189
  20. Ratnam J, Teichberg VI. Neurofilament-light increases the cell surface expression of the N-methyl-d-aspartate receptor and prevents its ubiquitination. J. Neurochem. 2005;92:878–885
  21. Roberts RC, Roche JK, Conley RR. Synaptic differences in the postmortem striatum of subjects with schizophrenia: a stereological ultrastructural analysis. Synapse. 2005;56:185–197
  22. Roche KW, Standley S, McCallum J, Dune Ly C, Ehlers MD, Wenthold RJ. Molecular determinants of NMDA receptor internalization. Nat. Neurosci. 2001;4:794–802
  23. Sans N, Prybylowski K, Petralia RS, Chang K, Wang YX, Racca C, et al. NMDA receptor trafficking through an interaction between PDZ proteins and the exocyst complex. Nat. Cell Biol. 2003;5:520–530
  24. Schiffer HH. Glutamate receptor genes: susceptibility factors in schizophrenia and depressive disorders?. Mol. Neurobiol. 2002;25:191–212
  25. Sheng M, Pak DT. Glutamate receptor anchoring proteins and the molecular organization of excitatory synapses. Ann. N.Y. Acad. Sci. 1999;868:483–493
  26. Smith Y, Raju DV, Pare JF, Sidibe M. The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci. 2004;27:520–527
  27. Tao YX, Rumbaugh G, Wang GD, Petralia RS, Zhao C, Kauer FW, et al. Impaired NMDA receptor-mediated postsynaptic function and blunted NMDA receptor-dependent persistent pain in mice lacking postsynaptic density-93 protein. J. Neurosci. 2003;23:6703–6712
  28. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The Stanley Foundation brain collection and neuropathology consortium. Schizophr. Res. 2000;44:151–155
  29. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 2002;42:165–179
  30. Wenthold RJ, Prybylowski K, Standley S, Sans N, Petralia RS. Trafficking of NMDA receptors. Annu. Rev. Pharmacol. Toxicol. 2003;43:335–358
  31. Zigmond MJ, Castro SL, Keefe KA, Abercrombie ED, Sved AF. Role of excitatory amino acids in the regulation of dopamine synthesis and release in the neostriatum. Amino Acids. 1998;14:57–62

PII: S0920-9964(05)00249-5

doi: 10.1016/j.schres.2005.06.012

Schizophrenia Research
Volume 78, Issue 1 , Pages 87-93 , 1 October 2005

Article Tools

* Image Usage & Resolution